JP2018522880A5 - - Google Patents

Download PDF

Info

Publication number
JP2018522880A5
JP2018522880A5 JP2017568234A JP2017568234A JP2018522880A5 JP 2018522880 A5 JP2018522880 A5 JP 2018522880A5 JP 2017568234 A JP2017568234 A JP 2017568234A JP 2017568234 A JP2017568234 A JP 2017568234A JP 2018522880 A5 JP2018522880 A5 JP 2018522880A5
Authority
JP
Japan
Prior art keywords
cancer
dengue virus
denv
composition according
pfu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017568234A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018522880A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/040787 external-priority patent/WO2017004567A1/en
Publication of JP2018522880A publication Critical patent/JP2018522880A/ja
Publication of JP2018522880A5 publication Critical patent/JP2018522880A5/ja
Priority to JP2021113634A priority Critical patent/JP2021176862A/ja
Pending legal-status Critical Current

Links

JP2017568234A 2015-07-02 2016-07-01 デングウイルス及び樹状細胞による併用療法のための組成物及び方法 Pending JP2018522880A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021113634A JP2021176862A (ja) 2015-07-02 2021-07-08 デングウイルス及び樹状細胞による併用療法のための組成物及び方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562231351P 2015-07-02 2015-07-02
US62/231,351 2015-07-02
PCT/US2016/040787 WO2017004567A1 (en) 2015-07-02 2016-07-01 Compositions and methods for combination therapy with dengue virus and dendritic cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021113634A Division JP2021176862A (ja) 2015-07-02 2021-07-08 デングウイルス及び樹状細胞による併用療法のための組成物及び方法

Publications (2)

Publication Number Publication Date
JP2018522880A JP2018522880A (ja) 2018-08-16
JP2018522880A5 true JP2018522880A5 (enExample) 2019-08-08

Family

ID=57609586

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017568234A Pending JP2018522880A (ja) 2015-07-02 2016-07-01 デングウイルス及び樹状細胞による併用療法のための組成物及び方法
JP2021113634A Pending JP2021176862A (ja) 2015-07-02 2021-07-08 デングウイルス及び樹状細胞による併用療法のための組成物及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021113634A Pending JP2021176862A (ja) 2015-07-02 2021-07-08 デングウイルス及び樹状細胞による併用療法のための組成物及び方法

Country Status (8)

Country Link
US (6) US9730989B2 (enExample)
EP (1) EP3316897A4 (enExample)
JP (2) JP2018522880A (enExample)
CN (1) CN107921063A (enExample)
CA (1) CA2991212A1 (enExample)
DE (1) DE202016008300U1 (enExample)
MX (1) MX2018000052A (enExample)
WO (1) WO2017004567A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018522880A (ja) * 2015-07-02 2018-08-16 プライムヴァックス イミュノ−オンコロジー，インク． デングウイルス及び樹状細胞による併用療法のための組成物及び方法
CA2999881A1 (en) 2015-09-26 2017-03-30 PrimeVax Immuno-Oncology, Inc. Compositions and methods for producing dendritic cells
CA3082779A1 (en) * 2016-11-16 2018-05-24 PrimeVax Immuno-Oncology, Inc. Combination immunotherapies for treatment of cancer
CA3049225A1 (en) * 2017-01-04 2018-07-12 PrimeVax Immuno-Oncology, Inc. Compositions and methods for therapy with dengue virus
US12274725B2 (en) 2017-06-12 2025-04-15 Washington University Zika virus strains for treatment of glioma
SG11201912163WA (en) * 2017-06-15 2020-01-30 Primevax Immuno Oncology Inc Compositions and methods for cancer therapy with dengue virus and dendritic cells

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1015972A (en) 1905-09-25 1912-01-30 Westinghouse Electric & Mfg Co Electric switch.
US1035755A (en) 1908-07-21 1912-08-13 Glenn S Smith Draftsman's apparatus.
US6429199B1 (en) * 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
AU2872199A (en) * 1998-02-20 1999-09-06 Rockefeller University, The Apoptotic cell-mediated antigen presentation to dendritic cells
US6048686A (en) * 1998-05-05 2000-04-11 Randy Kyle Brown Hyperthermia and immunotherapy for cancer
US6524587B1 (en) 1998-05-05 2003-02-25 Bruce W. Lyday Hyperthermia and immunotherapy for leukemias lymphomas, and solid tumors
AU4040200A (en) * 1999-03-26 2000-10-16 Walter Reed Army Institute Of Research Attenuated dengue-2 virus vaccine
ATE419006T1 (de) 1999-03-26 2009-01-15 Us Army Multivalenter dengue-virus impfstoff
CN1353575A (zh) 1999-03-31 2002-06-12 匹兹堡大学联邦制高等教育 用树状细胞一肿瘤细胞或树状细胞一病毒细胞衍生的免疫原在体外诱导抗原特异性t－销细胞
EP1484064A1 (en) 2003-06-04 2004-12-08 Gesellschaft für Biotechnologische Forschung Therapeutical composition containing dentritic cells and use thereof
EP1775343A4 (en) * 2004-06-24 2007-11-14 Dnavec Research Inc ANTITUM-AGENT WITH DENDRITIC CELL WITH THE TRANSFECTED RNA VIRUS
US8513008B2 (en) 2004-10-07 2013-08-20 Argos Therapeutics, Inc. Mature dendritic cell compositions and methods for culturing same
WO2006127150A2 (en) * 2005-04-08 2006-11-30 Argos Therapeutics, Inc. Dendritic cell compositions and methods
BR122020023372B1 (pt) 2006-08-15 2021-11-30 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Vírus da dengue do tipo 3 (den3) atenuado e composição imunogênica
CA2700579A1 (en) * 2006-09-28 2008-04-03 Cedars-Sinai Medical Center Cancer vaccines and vaccination methods
WO2013188315A1 (en) * 2012-06-10 2013-12-19 Inviragen, Inc. Compositions and methods for administration of vaccines against dengue virus
RU2575978C2 (ru) 2010-03-15 2016-02-27 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Система и способ получения и хранения активированных зрелых дендритных клеток
JP2014515367A (ja) 2011-05-26 2014-06-30 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 不活性化デング熱ウイルスワクチン
EP2543386A1 (en) * 2011-07-05 2013-01-09 Sotio a.s. Means and methods for active cellular immunotherapy of cancer by using tumor cells killed by high hydrostatic pressure
US9879003B2 (en) 2012-04-11 2018-01-30 Dana-Farber Cancer Institute, Inc. Host targeted inhibitors of dengue virus and other viruses
SG11201606625RA (en) 2014-02-14 2016-09-29 Immune Design Corp Immunotherapy of cancer through combination of local and systemic immune stimulation
US20180127717A1 (en) 2015-05-07 2018-05-10 Baylor College Of Medicine Dendritic cell immunotherapy
JP2018522880A (ja) 2015-07-02 2018-08-16 プライムヴァックス イミュノ−オンコロジー，インク． デングウイルス及び樹状細胞による併用療法のための組成物及び方法
CA2999881A1 (en) 2015-09-26 2017-03-30 PrimeVax Immuno-Oncology, Inc. Compositions and methods for producing dendritic cells
CA3082779A1 (en) 2016-11-16 2018-05-24 PrimeVax Immuno-Oncology, Inc. Combination immunotherapies for treatment of cancer
CA3049225A1 (en) 2017-01-04 2018-07-12 PrimeVax Immuno-Oncology, Inc. Compositions and methods for therapy with dengue virus
SG11201912163WA (en) 2017-06-15 2020-01-30 Primevax Immuno Oncology Inc Compositions and methods for cancer therapy with dengue virus and dendritic cells

Similar Documents

Publication Publication Date Title
JP2018522880A5 (enExample)
Tfouni et al. Biological activity of ruthenium nitrosyl complexes
JP2016531927A5 (enExample)
MX2022006107A (es) Metodos y composiciones para dosificacion en terapia celular adoptiva.
WO2015193359A3 (en) Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (cll)
MA39907A (fr) Nouvelle immunothérapie contre plusieurs tumeurs, du sang, notamment la leucémie aiguë myéloïde (lam)
JP2013177430A5 (enExample)
WO2015013461A3 (en) Cancer vaccination with antigen evolution
NZ616304A (en) Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
PH12021551208A1 (en) Novel immunotherapy against several tumors, such as lung cancer, including nsclc
PH12015502638A1 (en) Novel immunotherapy against several tumors, such as lung cancer, including nsclc
GB0700058D0 (en) Anti-tumor vaccine based on normal cells
MX2014009628A (es) Uniones a cdim y sus usos.
NZ711946A (en) Newcastle disease viruses and uses thereof
EA201291195A1 (ru) Усовершенствованная терапия рака на основе опухолеассоциированных антигенов, полученных из циклина d1
MX379423B (es) Inmunoterapia personalizada contra diversos tumores cerebrales y neuronales.
MX376066B (es) Anticuerpos dirigidos contra cd127.
BR112013031084A2 (pt) meios e métodos para imunoterapia celular ativa de câncer usando células tumorais mortas por alta pressão hidrostática e células dendríticas
EP2574170A4 (en) IMMUNOSTIMULATORY AND VACCINE COMPOSITIONS
WO2016073595A8 (en) T cells and dendritic cells for polyomavirus therapy
CN104245736A (zh) 抗人死亡受体5胞外区的人源化单克隆抗体
WO2015140172A3 (en) A medicament for use in a method of inducing or extending a cellular cytotoxic immune response
MX2021003826A (es) Benralizumab para usarse en el tratamiento de asma incrementando el volumen espiratorio forzado.
WO2017041092A3 (en) Anti-survivin antibodies for cancer therapy
WO2020023776A3 (en) Compositions and methods for inhibiting cancers and viruses